Abstract 1937P
Background
The role of adjuvant chemotherapy for patients with a resected extremity soft tissue sarcoma (STS) is controversial. Prior individual patient data meta-analyses are limited by omission of certain randomized controlled trials. The objective of this systematic review was to reassess the efficacy of adjuvant chemotherapy in resected STS, harnessing the ability of a new method termed Kaplan Meier (KM) subtraction to obtain patient level information.
Methods
A comprehensive literature search was performed to identify RCTs of adjuvant chemotherapy for adult patients diagnosed with localized resectable soft-tissue sarcoma. We searched PubMed, Web of Science, Cochrane Controlled Trials Register, UKCCCR Register of Cancer Trials, Physicians Data Query, EMBASE, MEDLINE and CancerLit (until December 2022). Data on the following endpoints were evaluated: disease free survival (DFS) and overall survival (OS). Data were summarized as hazard ratios (HR) with 95% confidence intervals (CI). Two reviewers independently assessed eligibility and quality of the studies using a modified version of the Detsky Quality Scale. The outcome measures were disease free survival (DFS) and overall survival (OS) calculated through the fixed effect or random effect model. We applied KM subtraction in R to obtain individual patient level data from the trials for subsequent metanalysis.
Results
A total of 24 trials representing 5936 patients were be included in the final analysis. The disease-free survival hazard ratio was 1.76 (95% CI 1.38-2.24) in favour of adjuvant chemotherapy. The overall survival hazard ratio was 1.30 (95% CI 1.11-1.53) favouring adjuvant chemotherapy. For adjuvant chemotherapy with doxorubicin alone, the hazard ratio of DFS and OS were 1.78 (95% CI 1.10-2.88) and 1.47 (95% 1.01-2.13).
Conclusions
This is the largest individual patient meta-analysis to-date of adjuvant doxorubicin and ifosfamide based chemotherapy in localized resectable soft-tissue sarcoma, and confirms a survival benefit (particularly for single-agent doxorubicin) with respect to disease free survival and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15